Breaking News, Collaborations & Alliances

Protagen, UCSF Enter Collaboration

Using Protagen’s SeroTag to investigate the immuno-profiling of prostate cancer patients treated with checkpoint inhibitors

Protagen AG has announced the start of a collaboration with the University of California, San Francisco (UCSF) to utilize Protagen’s SeroTag® technology to investigate the immuno-profiling of prostate cancer patients treated with checkpoint inhibitors and therapeutic vaccines. Through the collaboration, Protagen and UCSF intend to provide further insight into utilizing immune system profiling to predict treatment response and monitor prostate cancer patients for irAEs, specifically, a so-call...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters